Opioid CDS Recommendation 8 ECA Rule (id = "opioidcds-08")

<?xml version="1.0" encoding="UTF-8"?>


    
    (Details : {http://terminology.hl7.org/CodeSystem/plan-definition-type code 'eca-rule'
           = 'ECA Rule', given as 'ECA Rule'}): Clinicians should incorporate into the management plan strategies to mitigate risk,
         including considering offering naloxone when factors that increase risk for opioid overdose,
         such as history of overdose, history of substance use disorder, higher opioid dosages
         (≥50 MME/day), or concurrent benzodiazepine use, are present.(Details : {urn:iso:std:iso:3166 code 'US' = 'United States of America', given as 'United
           States of America'}): CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication
         between providers and patients about the risks and benefits of opioid therapy for chronic
         pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated
         with long-term opioid therapy, including opioid use disorder and overdose. The Guideline
         is not intended for patients who are in active cancer treatment, palliative care, or end-of-life
         care.: Before starting and periodically during continuation of opioid therapy, clinicians should
         evaluate risk factors for opioid-related harms.: Checking if the trigger prescription meets the inclusion criteria for recommendation
           #8 workflow.
    
        
        
    
    
    
    
    
        
            
            
            
        
    
    
    
    
    Clinicians should incorporate into the management plan strategies to mitigate risk, including
   considering offering naloxone when factors that increase risk for opioid overdose, such
   as history of overdose, history of substance use disorder, higher opioid dosages (≥50
   MME/day), or concurrent benzodiazepine use, are present.
    
        
            
            
            
        
        
            
                
                
                
            
        
    
    
        
            
            
            
        
        
            
                
                
                
            
        
    
    
        
            
            
            
        
    
    CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication
   between providers and patients about the risks and benefits of opioid therapy for chronic
   pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated
   with long-term opioid therapy, including opioid use disorder and overdose. The Guideline
   is not intended for patients who are in active cancer treatment, palliative care, or end-of-life
   care.
    Before starting and periodically during continuation of opioid therapy, clinicians should
   evaluate risk factors for opioid-related harms.
    
    
        
    
    
        
    
    
        
    
    
        
    
    
        
    
    
        
        
        https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chronic-pai
    n---united-states-2016#420
    
    
        
        
        
    
    
    
        
        
        Checking if the trigger prescription meets the inclusion criteria for recommendation #8
     workflow.
        
            
            
                <!--    We can use the example code systems from the FHIR CLinical Reasoning Module, or we
         can define GRADE specific code systems and use those here    -->
                
                    
                        
                            
                            
                            
                        
                    
                
                
                    
                        
                            
                            
                            
                        
                    
                
            
        
        
            
            
        
        
            
            
              Check whether the existing patient exhibits risk factors for opioid-related harms, such
         as concurrent use with benzodiazepine, a history of substance abuse, and/or an average
         MME greater than 50 mg/day.
              
              
            
        
        
        
        
        
            
            
              
              
            
        
        
            
            
              
              
            
        
        
            
            
              
              
            
        
        
            
            
        
        
            
        
        
            
        
    

<PlanDefinition xmlns="http://hl7.org/fhir">
  <id value="opioidcds-08"/> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="cds"/> 
  </extension> 
  <identifier> 
    <system value="urn:ietf:rfc:3986"/> 
    <value value="urn:oid:2.16.840.1.113883.4.642.11.10"/> 
  </identifier> 
  <identifier> 
    <use value="official"/> 
    <value value="cdc-opioid-guidance"/> 
  </identifier> 
  <version value="0.1.0"/> 
  <name value="Cdcopioid08"/> 
  <title value="CDC Opioid Prescribing Guideline Recommendation #8"/> 
  <type> 
    <coding> 
      <system value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/> 
      <code value="eca-rule"/> 
      <display value="ECA Rule"/> 
    </coding> 
  </type> 
  <status value="draft"/> 
  <date value="2018-03-19"/> 
  <publisher value="HL7 International / Clinical Decision Support"/> 
  <contact> 
    <telecom> 
      <system value="url"/> 
      <value value="http://www.hl7.org/Special/committees/dss"/> 
    </telecom> 
  </contact> 
  <description value="Clinicians should incorporate into the management plan strategies to mitigate risk,
   including considering offering naloxone when factors that increase risk for opioid
   overdose, such as history of overdose, history of substance use disorder, higher
   opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present."/> 
  <useContext>     <code>       <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>       <code value="focus"/>       <display value="Clinical Focus"/>     </code>     <valueCodeableConcept>       <coding>         <system value="http://snomed.info/sct"/>         <code value="182888003"/>         <display value="Medication requested (situation)"/>       </coding>     </valueCodeableConcept>   </useContext>   <useContext>     <code>       <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/>       <code value="focus"/>       <display value="Clinical Focus"/>     </code>     <valueCodeableConcept>       <coding>         <system value="http://snomed.info/sct"/>         <code value="82423001"/>         <display value="Chronic pain (finding)"/>       </coding>     </valueCodeableConcept>   </useContext>   <jurisdiction>     <coding>       <system value="urn:iso:std:iso:3166"/>       <code value="US"/>       <display value="United States of America"/>     </coding>   </jurisdiction>   <purpose value="CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve

   communication between providers and patients about the risks and benefits of opioid
   therapy for chronic pain, improve the safety and effectiveness of pain treatment,
   and reduce the risks associated with long-term opioid therapy, including opioid
   use disorder and overdose. The Guideline is not intended for patients who are in
   active cancer treatment, palliative care, or end-of-life care."/> 
  <usage value="Before starting and periodically during continuation of opioid therapy, clinicians

   should evaluate risk factors for opioid-related harms."/> 
  <copyright value="© CDC 2016+."/>   <topic>     <text value="Opioid Prescribing"/>   </topic>   <author>     <name value="Kensaku Kawamoto, MD, PhD, MHS"/>   </author>   <author>     <name value="Bryn Rhodes"/>   </author>   <author>     <name value="Floyd Eisenberg, MD, MPH"/>   </author>   <author>     <name value="Robert McClure, MD, MPH"/>   </author>   <relatedArtifact>     <type value="documentation"/>     <display value="CDC guideline for prescribing opioids for chronic pain"/>     <document>       <url value="https://guidelines.gov/summaries/summary/50153/cdc-guideline-for-prescribing-opioids-for-chro

      nic-pain---united-states-2016#420"/> 
    </document>   </relatedArtifact>   <relatedArtifact>     <type value="documentation"/>     <display value="MME Conversion Tables"/>     <document>       <url value="https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf"/>     </document>   </relatedArtifact>   <library value="http://example.org/fhir/Library/opioidcds-recommendation-08"/>   <action>     <extension url="http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation">      <valueCodeableConcept>         <coding>           <system value="http://terminology.hl7.org/CodeSystem/recommendation-strength"/>           <code value="strong"/>           <display value="Strong"/>         </coding>       </valueCodeableConcept>     </extension>     <extension url="http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence">      <valueCodeableConcept>         <coding>           <system value="http://terminology.hl7.org/CodeSystem/evidence-quality"/>           <code value="low"/>           <display value="Low quality"/>         </coding>       </valueCodeableConcept>     </extension>     <title value="Existing patient exhibits risk factors for opioid-related harms."/>     <description value="Checking if the trigger prescription meets the inclusion criteria for recommendation

     #8 workflow."/> 
    <documentation>       <type value="documentation"/>     </documentation>     <trigger>       <type value="named-event"/>       <name value="medication-prescribe"/>     </trigger>     <condition>       <kind value="applicability"/>       <expression>         <description value="Check whether the existing patient exhibits risk factors for opioid-related harms,

         such as concurrent use with benzodiazepine, a history of substance abuse, and/or
         an average MME greater than 50 mg/day."/> 
        <language value="text/cql-identifier"/>         <expression value="Inclusion Criteria"/>       </expression>     </condition>     <groupingBehavior value="visual-group"/>     <selectionBehavior value="exactly-one"/>     <dynamicValue>       <path value="action.description"/>       <expression>         <language value="text/cql-identifier"/>         <expression value="Get Detail"/>       </expression>     </dynamicValue>     <dynamicValue>       <path value="action.title"/>       <expression>         <language value="text/cql-identifier"/>         <expression value="Get Summary"/>       </expression>     </dynamicValue>     <dynamicValue>       <path value="action.extension"/>       <expression>         <language value="text/cql-identifier"/>         <expression value="Get Indicator"/>       </expression>     </dynamicValue>     <action>       <description value="Will offer Naloxone instead"/>     </action>     <action>       <description value="Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo"/>     </action>     <action>       <description value="N/A - see comment; snooze 3 mo"/>     </action>   </action> 


</

PlanDefinition

>